blue cross blue shield glp-1 coverage 2025 Insurance Changes for Medications in GLP-1 Drugs: What Employers Need
Description
Clinical studies evaluating the effect of GLP-1R agonism on neurodegeneration associated with AD are scarce
doi:10.1016/j.bmcl.2013.05.022 17
[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Capito M., Soares R
Although body mass index data were not available for this cohort, our findings suggest that any unmeasured obesity is likely to have been more prevalent in the GLP1 receptor agonist group, with any associated bias potentially moving the estimate towards increased risk of thyroid cancer
Notably, no significant difference in albuminuria was observed [82]
